EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry

Wonseok Yang iD, Sang-Won Lee iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70135 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Wonseok Yang und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea. Hauptthemen laut MEDLINE: Clinical Trials, Phase I as Topic, Neoplasms, Medical Oncology, Drug Industry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigated the success rate of Phase 1 clinical trial entry and the factors influencing it in oncology projects involving academia–industry collaboration during the discovery and preclinical stages. A total of 344 oncology projects in the discovery stage and 360 in the preclinical stage, initiated through collaborations with universities or hospitals between 2015 and 2019, were analyzed. The Phase 1 clinical trial entry success rates for oncology collaborative projects were 9.9% from the discovery stage and 24.2% from the preclinical stage. For discovery stage contracts, strong statistical significance was observed for contract type (co‐development OR 16.45, p = 0.008; licensing OR 42.43, p = 0.000) and technology (cell or gene therapy OR 3.82, p = 0.008). In contrast, for preclinical stage contracts, significant changes were noted for cancer type (blood cancer OR 2.24, p = 0.004), while the year of contract signing showed a relatively weak statistical significance (OR 1.24, p = 0.021). No significant changes were observed concerning partner firm size and the partnership territory. This study sheds light on how the characteristics of partnerships influence the success rates of early‐phase research, providing valuable insights for future strategic planning in oncology drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase I as TopicNeoplasmsMedical OncologyDrug IndustryHumansUniversitiesCooperative BehaviorAcademia

Stichwörter der Autor:innen

academia‐industry collaborationclinical trial entrycollaboration characteristicsoncologyprobability of success

Autor:innen und Institutionen

  • School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea.

ORCID-Profile: Wonseok Yang, Sang-Won Lee

Zitieren

APA

Yang, W., & Lee, S. W. (2025). From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry. Clinical and Translational Science. https://doi.org/10.1111/cts.70135

Vancouver

Yang W, Lee SW. From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry. Clinical and Translational Science. 2025. doi:10.1111/cts.70135

BibTeX
@article{Yang2025,
  author = {Yang, Wonseok and Lee, Sang-Won},
  title = {From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70135}
}
Kostenlos starten →